Lexicon Pharmaceuticals, Inc.
General ticker "LXRX" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $311.7M (TTM average)
Lexicon Pharmaceuticals, Inc. follows the US Stock Market performance with the rate: 56.0%.
Estimated limits based on current volatility of 1.9%: low 1.36$, high 1.42$
Factors to consider:
- Total employees count: 103 (-63.9%) as of 2024
- Top business risk factors: R&D success, Net losses and future profitability, Labor/talent shortage/retention, Intellectual property risks, Product liability
- Price in estimated range
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [0.56$, 1.57$]
- 2025-12-31 to 2026-12-31 estimated range: [0.58$, 1.57$]
Financial Metrics affecting the LXRX estimates:
- Positive: with PPE of -1.2 at the end of fiscal year the price was low
- Negative: negative Operating income
- Positive: 41.86 < Shareholder equity ratio, % of 48.91 <= 63.39
- Positive: Interest expense per share per price, % of 0 <= 0.01
- Negative: Operating cash flow per share per price, % of -74.85 <= 0.33
- Positive: -14.38 < Investing cash flow per share per price, % of -6.44
- Positive: Inventory ratio change, % of -23.30 <= -0.75
- Positive: Industry inventory ratio change (median), % of 0 <= 0
Short-term LXRX quotes
Long-term LXRX plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $0.14MM | $1.20MM | $31.08MM |
| Operating Expenses | $100.90MM | $172.95MM | $228.20MM |
| Operating Income | $-100.76MM | $-171.75MM | $-197.12MM |
| Non-Operating Income | $-1.18MM | $-5.37MM | $-3.29MM |
| R&D Expense | $52.82MM | $58.89MM | $84.48MM |
| Income(Loss) | $-101.94MM | $-177.12MM | $-200.40MM |
| Profit(Loss)* | $-101.94MM | $-177.12MM | $-200.40MM |
| Stockholders Equity | $117.12MM | $93.11MM | $145.95MM |
| Inventory | $0.00MM | $0.38MM | $0.23MM |
| Assets | $194.30MM | $229.43MM | $298.42MM |
| Operating Cash Flow | $-88.85MM | $-161.90MM | $-178.78MM |
| Capital expenditure | $1.33MM | $0.47MM | $1.03MM |
| Investing Cash Flow | $-71.08MM | $-49.94MM | $-15.38MM |
| Financing Cash Flow | $142.21MM | $187.96MM | $238.35MM |
| Earnings Per Share** | $-0.62 | $-0.80 | $-0.63 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.